RXi Selects Candidate in Anti-Scarring Program as Promised, But Will Likely Miss Partnership Goal | GenomeWeb

By Doug Macron

RXi Pharmaceuticals last week announced that it had selected a lead candidate from its anti-scarring program as the first compound it will move into human testing, meeting a previously stated corporate goal for 2010.

And while company's other goal for the year — the establishment of an industry partnership — remains an overall objective, RXi President and CEO Noah Beerman indicated that it may not happen until 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.